Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
LRMRthis companyLarimar Therapeutics, Inc.	$2.48	-1.68×	3.56×	0×	-1.19×	-55.3%	0.0%	0.0%	0.0%	-212.2%	-210.0%	-40.8%	0.05×	0.49×	0×	2.19×	0.0%	1	-2.84	2	C+
ALTAltimmune, Inc.	$2.18	-3.61×	1.41×	7,757.46×	-3.56×	-96.0%	100.0%	-230461.0%	-214861.0%	-39.2%	-35.4%	-21.2%	0.16×	0.09×	-57.76×	18.55×	0.0%	2	2.76	2	C+
ANNXAnnexon, Inc.	$4.28	-3.75×	3.68×	0×	-3.14×	-80.0%	0.0%	0.0%	0.0%	-97.7%	-91.0%	-24.0%	0.12×	0.66×	0×	5.68×	0.0%	1	-1.2	2	C
ANROAlto Neuroscience, Inc.	$27.89	-8.13×	3.4×	0×	-5.68×	-73.1%	0.0%	0.0%	0.0%	-41.8%	-38.2%	-10.1%	0.03×	2.86×	-26.88×	15.69×	0.0%	2	13.38	2	C+
KRROKorro Bio, Inc.	$15.22	-0.64×	1.46×	11.77×	-1.17×	-42.0%	33.0%	-1366.4%	-1834.5%	-228.0%	-83.8%	-105.1%	0.85×	-0.26×	0×	6.9×	0.0%	2	-1.99	1	C-
KYTXKyverna Therapeutics, Inc.	$5.09	-2.58×	1.79×	0×	-2.02×	-60.9%	0.0%	0.0%	0.0%	-69.4%	-65.0%	-36.9%	0.12×	0.6×	-347.29×	7.75×	0.0%	1	-0.9	2	C
Peer median	—	-3.61×	1.79×	0×	-3.14×	-73.1%	0.0%	0.0%	0.0%	-69.4%	-65.0%	-24.0%	0.12×	0.6×	-26.88×	7.75×	0.0%	2	-0.9	2	—